Navigation
banner
Together we Drive the Future

Complementary & Companion Diagnostics in Oncology

2017-05-232017-08-282017-07-28
EARLY BIRD DISCOUNT! Register by Jul 28, 2017 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


registration button

Cancer Therapeutics & Partnering Summit


Oncology Partnering & Deal-Making

Cancer Immunotherapy

Complementary & Companion Diagnostics in Oncology
 
 

Subscribe for updates



Dear Colleague,

Cancer Diagnostics have become fully ingrained in modern cancer treatment programs, and will continue to have an expanding role. Liquid biopsy approaches could exceed imaging in both sensitivity and specificity and yield more information on the tumor. The need for diagnostics for guiding immunotherapy is clear. Precision drug treatment and personal vaccines require a high resolution diagnostic of each tumor.

Technological advances have provided new levels of sensitivity that allow biomarker evaluation in the circulation, expanding the diversity of biomarker targets and facilitating time-based monitoring. In addition, information from the growing array of approaches has identified relevant molecules for targeted drug design. Together, these have facilitated a more intelligent approach to the development of therapy and its delivery to the cancer patient.

We invite you to attend the 3rd Complementary & Companion Diagnostics Conference, which will take place September 28-29, 2017 in San Diego, CA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss new research in cancer diagnostics, including next generation sequencing, the use of clinical utility of cell-free DNA liquid biopsy, patient selection for cancer drug development, and correlative predictive markers.

We hope to see you there! 
 

Best regards,

The 2017 Advisory Committee